Skip to main content
Top
Published in: Annals of Hematology 1/2016

01-01-2016 | Original Article

Loss of interleukin-21 leads to atrophic germinal centers in multicentric Castleman’s disease

Authors: Hidetaka Yajima, Motohisa Yamamoto, Yui Shimizu, Nodoka Sakurai, Chisako Suzuki, Yasuyoshi Naishiro, Kohzoh Imai, Yasuhisa Shinomura, Hiroki Takahashi

Published in: Annals of Hematology | Issue 1/2016

Login to get access

Abstract

Both multicentric Castleman’s disease (MCD) and immunoglobulin (Ig)G4-related disease (IgG4-RD) are systemic diseases, presenting with hypergammaglobulinemia and elevated serum levels of IgG4. However, with regard to histopathological findings, MCD shows atrophic germinal centers. On the other hand, expanded germinal centers are detected in IgG4-RD. We extracted germinal centers from specimens of each disorder by microdissection and analyzed the expression of mRNAs by real-time polymerase chain reaction to clarify the mechanisms underlying atrophied germinal centers in MCD. This analysis disclosed loss of interleukin (IL)-21 and B cell lymphoma (Bcl)-6 in the germinal centers of MCD. Loss of IL-21 is considered to be involved in the disappearance of Bcl-6 and leads to atrophied germinal centers in MCD.
Literature
1.
go back to reference Castleman B, Iverson L, Menendez VP (1956) Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer 9:822–830PubMedCrossRef Castleman B, Iverson L, Menendez VP (1956) Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer 9:822–830PubMedCrossRef
2.
go back to reference Chen KT (1984) Multicentric Castleman’s disease and Kaposi’s sarcoma. Am J Surg Pathol 8:287–293PubMedCrossRef Chen KT (1984) Multicentric Castleman’s disease and Kaposi’s sarcoma. Am J Surg Pathol 8:287–293PubMedCrossRef
3.
go back to reference Frizzera G (1988) Castleman’s disease and related disorders. Semin Diagn Pathol 5:346–364PubMed Frizzera G (1988) Castleman’s disease and related disorders. Semin Diagn Pathol 5:346–364PubMed
4.
go back to reference Umehara H, Olazaki K, Masaki Y et al (2012) Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Mod Rheumatol 22:21–30PubMedCrossRef Umehara H, Olazaki K, Masaki Y et al (2012) Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Mod Rheumatol 22:21–30PubMedCrossRef
5.
go back to reference Tanaka A, Moriyama M, Nakashima H et al (2012) Th2 and regulatory immune reactions contributes to IgG4 production and the initiation of Mikulicz’s disease. Arthritis Rheum 64:254–263PubMedCrossRef Tanaka A, Moriyama M, Nakashima H et al (2012) Th2 and regulatory immune reactions contributes to IgG4 production and the initiation of Mikulicz’s disease. Arthritis Rheum 64:254–263PubMedCrossRef
6.
go back to reference Sasaki M, Nakamura S, Ohyama Y et al (2000) Accumulation of common T cell clonotypes in the salivary glands of patients with human T lymphotropic virus type I-associated and idiopathic Sjögren’s syndrome. J Immunol 164:2823–2831PubMedCrossRef Sasaki M, Nakamura S, Ohyama Y et al (2000) Accumulation of common T cell clonotypes in the salivary glands of patients with human T lymphotropic virus type I-associated and idiopathic Sjögren’s syndrome. J Immunol 164:2823–2831PubMedCrossRef
7.
go back to reference Bowne WB, Lewis JJ, Filippa DA et al (1999) The management of unicentric and multicentric Castleman’s disease: a report of 16 cases and a review of the literature. Cancer 85:706–717PubMedCrossRef Bowne WB, Lewis JJ, Filippa DA et al (1999) The management of unicentric and multicentric Castleman’s disease: a report of 16 cases and a review of the literature. Cancer 85:706–717PubMedCrossRef
8.
go back to reference Yoshizaki K, Matsuda T, Nishimoto N et al (1989) Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman’s disease. Blood 74:1360–1367PubMed Yoshizaki K, Matsuda T, Nishimoto N et al (1989) Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman’s disease. Blood 74:1360–1367PubMed
9.
go back to reference van Rhee F, Wong RS, Munshi N et al (2014) Siltuximab for multicentric Castleman’s disease: a randomized, double-blind, placebo-controlled trial. Lancet Oncol 15:966–974PubMedCrossRef van Rhee F, Wong RS, Munshi N et al (2014) Siltuximab for multicentric Castleman’s disease: a randomized, double-blind, placebo-controlled trial. Lancet Oncol 15:966–974PubMedCrossRef
10.
go back to reference Paul-Pletzer K (2006) Tocilizumab: blockade of interleukin-6 signaling pathway as a therapeutic strategy for inflammatory disorders. Drugs Today (Barc) 42:559–576CrossRef Paul-Pletzer K (2006) Tocilizumab: blockade of interleukin-6 signaling pathway as a therapeutic strategy for inflammatory disorders. Drugs Today (Barc) 42:559–576CrossRef
11.
go back to reference Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T (2008) Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receeptor afer administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and castleman disease. Blood 112:3959–3964PubMedCrossRef Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T (2008) Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receeptor afer administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and castleman disease. Blood 112:3959–3964PubMedCrossRef
12.
go back to reference Butch AW, Chung GH, Hoffmann JW, Nahm MH (1993) Cytokine expression by germinal center cells. J Immunol 150:39–47PubMed Butch AW, Chung GH, Hoffmann JW, Nahm MH (1993) Cytokine expression by germinal center cells. J Immunol 150:39–47PubMed
13.
go back to reference Qi H, Liu D, Ma W, Wang Y, Yan H (2014) Bcl-6 controlled TFH polarization and memory: the known unknowns. Curr Opin Immunol 28:34–41PubMedCrossRef Qi H, Liu D, Ma W, Wang Y, Yan H (2014) Bcl-6 controlled TFH polarization and memory: the known unknowns. Curr Opin Immunol 28:34–41PubMedCrossRef
15.
go back to reference Park HJ, Kim DH, Lim SH et al (2014) Insights into the role of follicular helper T cells in autoimmunity. Immun Netw 14:21–29CrossRef Park HJ, Kim DH, Lim SH et al (2014) Insights into the role of follicular helper T cells in autoimmunity. Immun Netw 14:21–29CrossRef
16.
go back to reference Maehara T, Moriyama M, Nakashima H et al (2012) Interleukin-21 contributes to germinal center formation and immunoglobulin G4 production in IgG4-related dacryoadenitis and sialadenitis, so called Mikulicz’s disease. Ann Rheum Dis 71:2011–2019PubMedCrossRef Maehara T, Moriyama M, Nakashima H et al (2012) Interleukin-21 contributes to germinal center formation and immunoglobulin G4 production in IgG4-related dacryoadenitis and sialadenitis, so called Mikulicz’s disease. Ann Rheum Dis 71:2011–2019PubMedCrossRef
17.
go back to reference Sato Y, Kojima M, Takata K et al (2009) Systemic IgG4-related lymphadenopathy: a clinical and pathologic comparison to multicentric Castleman’s disease. Mod Pathol 22:589–599PubMedCrossRef Sato Y, Kojima M, Takata K et al (2009) Systemic IgG4-related lymphadenopathy: a clinical and pathologic comparison to multicentric Castleman’s disease. Mod Pathol 22:589–599PubMedCrossRef
Metadata
Title
Loss of interleukin-21 leads to atrophic germinal centers in multicentric Castleman’s disease
Authors
Hidetaka Yajima
Motohisa Yamamoto
Yui Shimizu
Nodoka Sakurai
Chisako Suzuki
Yasuyoshi Naishiro
Kohzoh Imai
Yasuhisa Shinomura
Hiroki Takahashi
Publication date
01-01-2016
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 1/2016
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-015-2500-2

Other articles of this Issue 1/2016

Annals of Hematology 1/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine